Page 38 - JSOM Fall 2024

Workgroup. West J Emerg Med. 2012;13(1):17–25. doi:10.5811/ 18. Barbic D, Andolfatto G, Grunau B, et al. Rapid agitation control
westjem.2011.9.6864 with ketamine in the emergency department: a blinded, random-
12. Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. ized controlled trial. Annul Emerg Med. 2021;78(6):788–795.
The psychopharmacology of agitation: consensus statement of doi:10.1016/j.annemergmed.2021.05.023
the American Association for Emergency Psychiatry Project BETA 19. Davies JA. Lorazepam. In: xPharm: The Comprehensive Pharma-
Psychopharmacology Workgroup. West J Emerg Med. 2012;13 cology Reference. Elsevier; 2007.
(1):26–34.doi:10.5811/westjem.2011.9.6866 20. Wermeling DPH, Miller JL, Archer SM, Manaligod JM, Rudy AC.
13. Knox DK, Holloman GH Jr. Use and avoidance of seclusion Bioavailability and pharmacokinetics of lorazepam after intrana-
and restraint: consensus statement of the American Association sal, intravenous, and intramuscular administration. J Clin Pharma-
for Emergency Psychiatry Project BETA Seclusion and Restraint col. 2001;41(11):1225–1231. doi:10.1177/00912700122012779
Workgroup. West J Emerg Med. 2012;13(1): 35–40. doi:10.5811/ 21. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and anal-
westjem.2011.9.6867 gesic effects of i.m. and oral ketamine. Br J Anaesth. 1981;53(8):
14. Mandel AA, Stanley B, Dent K, Jager-Hyman S, Ghahramanlou- 805–809. doi:10.1093/bja/53.8.805
Holloway M, Brown GK. Expert opinion on managing suicide 22. Singh V, Gillespie TW, Lane O, et al. A dose-escalation clinical
risk in deployed settings. Military Behavioral Health. 2022:10(3): trial of intranasal ketamine for uncontrolled cancer-related pain.
145–155. doi:10.1080/21635781.2021.1973624 Pharmacotherapy. 2022;42(4):298–310. doi:10.1002/phar.2669
15. Sall J, Brenner L, Millikan Bell AM, Colston MJ. Assessment 23. Schnellbacher S, O’Mara H. Identifying and managing malinger-
and management of patients at risk for suicide: synopsis of the ing and factitious disorder in the military. Curr Psychiatry Rep.
2019 U.S. Department of Veterans Affairs and U.S. Department 2016;18(11):105. doi:10.1007/s11920-016-0740-z
of Defense clinical practice guidelines. Ann Intern Med. 2019; 24. Solomon Z, Shklar R, Mikulincer M. Frontline treatment of
171(5):343–353. doi:10.7326/M19-0687 combat stress reaction: a 20-year longitudinal evaluation study.
16. Adler AB, Start AR, Milham L, et al. Rapid response to acute Am J Psychiatry. 2005;162(12):2309–2314. doi:10.1176/appi.
stress reaction: pilot test of iCOVER training for military units. ajp.162.12.2309
Psychol Trauma. 2020;12(4):431–435. https://doi.org/10.1037/
tra0000487 PMID: 39317405; DOI: 10.55460/78DD-BB0Y
17. Lin J, Figuerado Y, Montgomery A, et al. Efficacy of ketamine
for initial control of acute agitation in the emergency depart-
ment: a randomized study. Am J Emerg Med. 2021:44:306–311.
doi:10.1016/j.ajem.2020.04.013

TAKE
TAKE Get Dramatic Relief Fast
CHARGE
CHARGE Alpha-Stim is the drug-free,
®
OF YOUR
OF YOUR clinically proven treatment to
alleviate anxiety, insomnia, and pain.
INSOMNIA
INSOMNIA Alpha-Stim is an FDA-cleared,
easy-to-use handheld prescription
medical device that treats
insomnia without lasting side
effects or risk of addiction.

Get started at alpha-stim.com.

© 2023 Electromedical Products International, Inc. All rights reserved.
Alpha-Stim and the Alpha-Stim logo are registered trademarks of
Electromedical Products International, Inc. Read a full disclosure of the
minor and self-limiting risks here: alpha-stim.com/risk.

36 | JSOM Volume 24, Edition 3 / Fall 2024